Mitochondria, synaptic plasticity, and schizophrenia

International Review of Neurobiology

Volumn 59, Issue , 2004, Pages 273-296

  Ben Shachar, Dorit ^a   Laifenfeld, Daphna ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CALCIUM SIGNALING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; METABOLISM; MITOCHONDRION; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SYNAPSE;

ANIMALS; CALCIUM SIGNALING; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURONAL PLASTICITY; SCHIZOPHRENIA; SYNAPSES;

EID: 2342562466     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)59011-6     Document Type: Article

References (164)

1. Adams, C. E., DeMasters, B. K., and Freedman, R. (1995). Regional zinc staining in postmortem hippocampus from schizophrenic patients. Schizophr. Res. 18, 71-77.
2. Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., and Freedman, R. (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24, 189-202.
3. Akbarian, S., Vinuela, A., Kim, J. J., Potkin, S. G., Bunney, W. E., Jr., and Jones, E. G. (1993). Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch. Gen. Psychiat. 50, 178-187.
4. Akyol, O., Herken, H., Uz, E., Fadillioglu, E., Unal, S., Sogut, S., Ozyurt, H., and Savas, H. A. (2002). The incides of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: The possible role of oxidant/antioxidant imbalance. Prog. Neuro. Psychopharmacol. Biol. Psychiat. 26, 995-1005.
5. Albensi, B. C., Sullivan, P. G., Thompson, M. B., Scheff, S. W., and Mattson, M. P. (2000). Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol. 162, 385-389.
6. Altshuler, L. L., Conrad, A., Kovelman, J. A., and Scheibel, A. (1987). Hippocampal Pyramidal cell orientation in schizophrenia. Arch. Gen. Psychiat. 44, 1094-1098.
7. Andreasen, N. C., OwLeary, D. S., Flaum, M., Nopoulos, P., Watkins, G. L., Boles Ponto, L. L. B., and Hichwa, R. D. (1997). Hypofrontality in schizophrenia: Disturbed dysfunctional circuits in neuroleptic-naive patients. Lancet 349, 1730-1734.
8. Arnaiz, S. L., Coronel, M. F., and Boveris, A. (1999). Nitric oxide, superoxide and hydrogen peroxide production in brain mitochondria after haloperidol treatment. Nitric Oxide Biol. Chem. 3, 235-243.
9. Arnold, S. E. (1999). Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology. Dev. Psychopathol. 11, 439-456.
10. Arnold, S. E., Franz, B. R., Gur, R. C., Gur, R. E., Shapiro, R. M., Moberg, P. J., and Trojanowski, J. Q. (1995). Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am. J. Psychiat. 152, 738-748.
11. Arnold, S. E., Hyman, B. T., Van Hoesen, G. W., and Damasio, A. R. (1991a). Some cytoarchitechtural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiat. 48, 625-632.
12. Arnold, S. E., Lee, V. M., Gur, R. E., and Trojanowski, J. Q. (1991b). Abnormal expression of two microtuble-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc. Natl. Acad. Sci. USA 88, 10850-10854.
13. Balijepalli, S., Boyd, M. R., and Ravindranath, V. (1999). Inhibition of mitochondrial complex I by haloperidol: The role of thiol oxidation. Neuropsychopharmacology 38, 567-577.
14. Balijepalli, S., Kenchappa, R. S., Boyd, M. R., and Ravindfanath, V. (2001). Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: Comparison with atypical antipsychotics. Neurochem. Inter. 38, 425-435.
15. Barrientos, A., Marin, C., Miro, O., Casademont, J., Gomez, M., Nunes, V., Tolosa, E., Urbano-Marquez, A., and Cardellach, F. (1998). Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. J. Neurosci. Res. 53, 475-481.
16. Benes, F. M., Sorensen, I., and Bird, E. D. (1991). Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr. Bull. 17, 597-608.
17. Ben-Shachar, D. (2002). Mitochondrial dysfunction in schizophrenia: A possible linkage to dopamine. J. Neurochem. 83, 1241-1251.
18. Ben-Shachar, D., Zuk, R., Gazawi, H., Reshef, A., Sheinkman, A., and Klein, E. (1999). Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int. J. Neuropsychopharmacol. 2, 245-253.
19. Ben-Shachar, D., Zuk, R., and Glinka, Y. (1995). Dopamine neurotoxicity: Inhibition of mitochondrial respiration. J. Neurochem. 64, 718-723.
20. Berman, S. B., and Hatings, T. G. (1999). Dopamine oxidation alters mitochondrial respiration and induces transition in brain mitochondria: Implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
21. Bernstein, H. G., Krell, D., Braunewell, K. H., Baumann, B., Gundelfinger, E. D., Diekmann, S., Danos, P., and Bogerts, B. (2001). Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J. Neurocytol. 30, 661-670.
22. Bernstein, H. G., Stanarius, A., Baumann, B., Henning, H., Krell, D., Danos, P., Falkai, P., and Bogerts, B. (1998). Nitric oxide synthase-containing neurons in the human hypothalamus: Reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83, 867-875.
23. Bissiere, S., Humeau, Y., and Luthi, A. (2003). Dopamine gates LTP induction in lateral amygdala by suppressing feedforward inhibition. Nature Neurosci. 6, 587-592.
24. Black, J. E., Zelazny, A. M., and Greenough, W. T. (1991). Capillary and mitochondrial support of neural plasticity in adult rat visual cortex. Exp. Neurol. 111, 204-209.
25. Bleuler, E. (1911). In "Dementia Praecox or the Group of Schizophrenians" (J. Zinkin, Ed.). International University Press, New York.
26. Breese, C. R., Freedman, R., and Leonard, S. S. (1995). Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674, 82-90.
27. Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. A., deBartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., and Pickar, D. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94, 2569-2574.
28. Brene, S., Messer, C., and Nestler, E. J. (1998). Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: Regulation by haloperidol. Neuroscience 84, 813-823.
29. Brodin, L., Bakeeva, L., and Shupliakov, O. (1999). Presynaptic mitochondria and the temporal pattern of neurotransmitter release. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354(1381), 365-372.
30. Buchsbaum, M. S., and Hazlett, E. A. (1998). Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 24, 343-346.
31. Bunney, B. G., Potkin, S. G., and Bunney, W. E., Jr. (1995). New morphological and neuropathological findings in schizophrenia: A neurodevelopmental perspective. Clin. Neurosci. 3, 81-88.
32. Burkhardt, C., Kelly, J. P., Lim, Y. H., Filley, C. M., and Parker, W. D. (1993). Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33, 512-517.
33. Calabresi, P., Gubellini, P., Picconi, B., Centonze, D., Pisani, A., Bonsi, P., Greengard, P., Hipskind, R. A., Borrelli, E., and Bernardi, G. (2001). Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21, 5110-5120.
34. Callicott, J. H., Egan, M. F., Bertolino, A., Mattay, V. S., Langheim, F. J., Frank, J. A., and Weinberger, D. R. (1998). Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biol. Psychiat. 44, 941-950.
35. Cannon, T. D., Rosso, I. M., Bearden, C. E., Sanchez, L. E., and Hadley, T. (1999). A prospective cohort study of neurodevelopmental processes in the genesis and epigenesis of schizophrenia. Dev. Psychopathol. 11, 467-485.
36. Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsych-pharmacology 1, 179-186.
37. Carlsson, A., Hansson, L. O., Waters, N., and Carlsson, M. L. (1999a). A glutamatergic deficiency model of schizophrenia. Br. J. Psychiat. Suppl. 37, 2-6.
38. Carlsson, A., Waters, N., and Carlsson, M. L. (1999b). Neurotransmitter interactions in schizophrenia: Therapeutic implications. Biol. Psychiat. 46, 1388-1395.
39. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., and Carlsson, M. L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260.
40. Carroll, R. C., and Zukin, R. S. (2002). NMDA-receptor trafficking and targeting: Implications for synaptic transmission and plasticity. Trends Neurosci. 25, 571-577.
41. Carter, C. S., Perlstein, W., Ganguli, R., Brar, J., Mintun, M., and Cohen, J. D. (1998). Functional hypofrontality and working memory dysfunction in schizophrenia. Am. J. Psychiat. 155, 1285-1287.
42. Cavelier, L., Jazin, E., Eriksson, I., Prince, J., Bave, B., Oreland, L., and Gyllensten, U. (1995). Decreased cytochrome c oxidase activity and lack of age related accumulation of mtDNA in brain of schizophrenics. Genomics 29, 217-228.
43. Ceriello, A. (2003). New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26, 1589-1596.
44. Chan, P., Di Monte, D. A., Luo, J. J., DeLanney, L. E., Irwin, I., and Langston, J. W. (1994). Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 2484-2487.
45. Chua, S. E., and McKenna, P. J. (1995). Schizophrenia: A brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br. J. Psychiat. 166, 563-582.
46. Chua, S. E., and Murray, R. M. (1996). The neurodevelopmental theory in schizophrenia: Evidence concerning structure and neuropsychology. Ann. Med. 28, 547-555.
47. Cohen, G., Farooqui, R., and Kesler, N. (1997). Parkinson's disease: A new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA 94, 4890-4894.
48. Conrad, A. J., and Scheibel, A. B. (1987). Schizophrenia and the hippocampus: The embryological hypothesis extended. Schizophr. Bull. 13, 577-587.
49. Das, I., Khan, N. S., Pun, B. K., Sooranna, S. R., de Belleroche, J., and Hirsch, S. R. (1995). Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun. 212, 375-380.
50. Davey, G. P., Peuchen, S., and Clark, J. B. (1998). Energy thresholds in brain mitochondria: Potential involvement in neurodegeneration. J. Biol. Chem. 273, 12753-12757.
51. Davis, K. L., Kann, R. S., Ko, G., and Davidson, M. (1991). Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiat. 148, 1474-1486.
52. Dawirs, R. R., Hildebrandt, K., and Teuchert-Noodt, G. (1998). Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J. Neural Transm. 105, 317-327.
53. De Souza, I. E., McBean, G. J., and Meredith, G. E. (1999). Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur. J. Pharmacol. 382, 139-142.
54. Deakin, J. F., Slater, P., Simpson, M. D., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., and Cross, A. J. (1989). Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52, 1781-1786.
55. DeLisi, L. E. (1997). The genetics of schizophrenia: Past, present, and future concepts. Schizophr. Res. 28, 163-175.
56. Dror, N., Klein, E., Karry, R., Sheinkman, A., Kirsh, Z., Mazor, M., Tzukerman, M., and Ben-Shachar, D. (2002). State dependent alterations in mitochondrial complex I activity in platelets: A potential peripheral marker for schizophrenia. Mol. Psychiat. 7, 995-1001.
57. Dwork, A. J. (1997). Postmortem studies of the hippocampal formation in schizophrenia. Schizophr. Bull. 23, 385-402.
58. Eastwood, S. L., Burnet, P. W., and Harrison, P. J. (1995). Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66, 309-319.
59. Eastwood, S. L., and Harrison, P. J. (1999). Detection and quantification of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin-fixed, paraffin wax-embedded sections. Neuroscience 93, 99-106.
60. Elkashef, A. M., Al-Barazi, H., Venable, D., Baker, I., Hill, J., Apud, J., and Wyatt, R. J. (2002). Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls. Prog. Neuropsychopharmacol. Biol. Psychiat. 26, 145-148.
61. Elmarakby, A. A., Williams, J. M., and Pollock, D. M. (2003). Targeting sources of superoxide and increasing nitric oxide bioavailability in hypertension. Curr. Opin. Invest. Drugs 4, 282-290.
62. Eyles, D. W., McGrath, J. J., and Reynolds, G. P. (2002). Neuronal calcium-binding proteins and schizophrenia. Schizophr. Res. 57, 27-34.
63. Fujimoto, T., Nakano, T., Takano, T., Hokazono, Y., Asakura, T., and Tsuji, T. (1992). Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr. Scand. 86, 455-462.
64. Gage, F. H. (2000). Mammalian neural stem cells. Science 287, 1433-1438.
65. Gioio, A. E., Eyman, M., Zhang, H., Lavina, Z. S., Giuditta, A., and Kaplan, B. B. (2001). Local synthesis of nuclear-encoded mitochondrial proteins in the presynaptic nerve terminal. J. Neurosci. Res. 64, 447-453.
66. Giulivi, G. (1998). Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism. Biochem. J. 332, 673-679.
67. Goldsmith, S. K., and Joyce, J. N. (1995). Alterations in hippocampal mossy fiber pathway in schizophrenia and Alzheimer's disease. Biol. Psychiat. 37, 122-126.
68. Green, M. F. (1996). what are the functional consequences of neurocognitive deficits in schizophrenia. Am. J. Psychiat. 153, 321-330.
69. Grosshans, D. R., Clayton, D. A., Coultrap, S. J., and Browning, M. D. (2002). Analysis of glutamate receptor surface expression in acute hippocampal slices. Sci. STKE. 137, PL8.
70. Guldner, F. H., Bahar, E., Young, C. A., and Ingham, C. A. (1997). Structural plasticity of optic synapses in the rat suprachiasmatic nucleus: Adaptation to long-term influence of light and darkness. Cell Tissue Res. 287, 43-60.
71. Gur, R. E., Resnick, S. M., Alavi, A., Gur, R. C., Caroff, S., Dann, R., Silver, F. L., Saykin, A. J., Chwluk, J. B., and Kudhner, M. (1987). Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch. Gen. Psychiat. 44, 126-129.
72. Harrison, P. J. (1999). The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain 122(Pt. 4), 593-624.
73. Hatefi, Y. (1985). The mitochondrial electron transport and oxidative phosphorylation system. Annu. Rev. Biochem. 54, 1015-1069.
74. Hazlett, E. A., Buchsbaum, M. S., Byne, W., Wei, T. C., Spiegel-Cohen, J., Geneve, C., Kinderlehrer, R., Haznedar, M. M., Shihabuddin, L., and Siever, L. J. (1999). Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatr. 156, 1190-1199.
75. Hazlett, E. A., Buchsbaum, M. S., Jeu, L. A., Nenadic, I., Fleischman, M. B., Shihabuddin, L., Haznedar, M. M., and Harvey, P. D. (2000). Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning tasks. Schizophr. Res. 43, 33-46.
76. Hevner, R. F., and Wong-Riley, M. (1991). Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analyzed by in situ hybridization: Comparison with CO activity and protein. J. Neurosci. 11, 1942-1958.
77. Heynen, A. J., Quinlan, E. M., Bae, D. C., and Bear, M. F. (2000). Bidirectional, activity-dependent regulation of glutamate receptors in the adult hippocampus in vivo. Neuron 28, 527-536.
78. Hietala, J., and Syvalahti, E. (1996). Dopamine in schizophrenia. Ann. Med. 28, 557-561.
79. Holcomb, H. H., Cascella, N. G., Thaker, G. K., Medoff, D. R., Dannals, R. F., and Tamminga, C. A. (1996). Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiat. 153, 41-49.
80. Honer, W. G., Falkai, P., Young, C., Wang, T., Xie, J., Bonner, J., Hu, L., Boulianne, G. L., Luo, Z., and Trimble, W. S. (1997). Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience 78, 99-110.
81. Javitt, D. C., and Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 148, 1301-1308.
82. Jensen, J. E., Al-Semaan, Y. M., Williamson, P. C., Neufeld, R. W., Menon, R. S., Schaeffer, B., Densmore, M., and Drost, D. J. (2002). Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 tesla. Br. J. Psychiat. 180, 39-44.
83. Kaminska, B., Kaczmarek, L., Larocque, S., and Chaudhuri, A. (1997). Activity-dependent regulation of cytochrome b gene expression in monkey visual cortex. J. Comp. Neurol. 379, 271-282.
84. Knapp, L. T., and Klann, E. (2002). Role of reactive oxygen species in hippocampal long-term potentiation: Contributory or inhibitory? J. Neurosci. Res. 70, 1-7.
85. Kapur, S., and Remington, G. (2001). Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol. Psychiat. 50, 873-883.
86. Karson, C. N., Griffin, W. S., Mrak, R. E., Husain, M., Dawson, T. M., Snyder, S. H., Moore, N. C., and Sturner, W. Q. (1996). Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis. Mol. Chem. Neuropathol. 27, 275-284.
87. Kelley, J. J., Gao, X. M., Tamminga, C. A., and Roberts, R. C. (1997). The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp. Neurol. 146, 471-478.
88. Kennea, N. L., and Mehmet, H. (2002). Neuronal stem cells. J. Pathol. 197, 536-550.
89. Kerwin, R., Patel, S., and Meldrum, B. (1990). Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39, 25-32.
90. Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., and Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
91. Kinderlehrer, R., Haznedar, M. M., Shihabuddin, L., and Siever, L. J. (1999). Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiat. 156, 1190-1199.
92. Krystal, J. H., Bennett, A., Abi-Saab, D., Belger, A., Karper, L. P., D'Souza, D. C., Lipschitz, D., Abi-Dargham, A., and Charney, D. S. (2000). Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiat. 47, 137-143.
93. Krystal, J. H., D'Souza, D. C., Petrakis, I. L., Belger, A., Berman, R. M., Charney, D. S., Abi-Saab, W., and Madonick, S. (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapics in neuropsychiatric disorders. Harv. Rev. Psychiat. 7, 125-143.
94. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B., Jr., and Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat. 51, 199-214.
95. Kuloglu, M., Atmaca, M., Tezcan, E., Ustundag, B., and Bulut, S. (2002). Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 20, 171-175.
96. Kung, L., and Roberts, R. C. (1999). Mitochondrial pathology in human schizophrenic striatum: A postmortem ultrastructural study. Synapse 31, 67-75.
97. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., and Innis, R. (1999). Increased dopamine transmission in schizophrenia: Relationship to illness phase. Biol. Psych. 46, 56-72.
98. Lahti, A. G., Holcomb, H. H., Medoff, D. R., Weiler, M. A., Tamminga, C. A., and Carpenter, W. T., Jr. (2001). Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiat. 158, 1797-1808.
99. Lewis, D. A., Pierri, J. N., Volk, D. W., Melchitzky, D. S., and Woo, T. U. W. (1999). Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol. Psychiat. 46, 616-626.
100. Lewis, D. A. (1997). Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 16, 385-398.
101. Li, S., Cullen, W. K., Anwyl, R., and Rowan, M. J. (2003). Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nature Neurosci. 6, 526-531.
102. Mahadik, S. P., Evans, D., and Harbanns, L. (2001). Oxidative stress and role for antioxidant ω-3 essential fatty acid supplementation in schizophrenia. Prog. Neuro. Psychopharmacol. Biol. Psychiat. 25, 463-493.
103. Malenka, R. C., and Nicoll, R. A. (1999). Long-term potentiation: A decade of progress? Science 285, 1870-1874.
104. Manahan-Vaughan, D., and Kulla, A. (2003). Regulation of depotentiation and long-term potentiation in the dentate gyrus of freely moving rats by dopamine D2-like receptors. Cereb. Cortex 13, 123-135.
105. Manoach, D. S., Press, D. Z., Thangaraj, V., Searl, M. M., Goff, D. C., Halpern, E., Saper, C. B., and Warach, S. (1999). Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol. Psychiat. 45, 1128-1137.
106. Marenco, S., and Weinberger, D. R. (2000). The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Dev. Psychopathol. 12, 501-527.
107. Matthysse, S. (1974). Dopamine and the pharmacology of schizophrenia: The state of the evidence. J. Psychiatr. Res. 11, 107-113.
108. Mattson, M. P. (1999). Establishment and plasticity of neuronal polarity. J. Neurosci. Res. 57, 577-589.
109. Mattson, M. P., LaFerla, F. M., Chan, S. L., Leissring, M. A., Shepel, P. N., and Geiger, J. D. (2000). Calcium signaling in the ER: Its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 23, 222-229.
110. Mattson, M. P., and Liu, D. (2002). Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromol. Med. 2, 215-231.
111. Maurer, I., and Moller, H. J. (1997). Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell Biochem. 174, 255-259.
112. McGlashan, T. H. (1988). A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr. Bull. 14, 515-542.
113. McGlashan, T. H., and Fenton, W. S. (1992). The positive/negative distinction in schizophrenia: Review of natural history validators. Arch. Gen. Psychiat. 49, 63-72.
114. McGlashan, T. H., and Hoffman, R. E. (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiat. 57, 637-648.
115. Melamed-Book, N., and Rahamimoff, R. (1998). The revival of the role of the mitochondria in regulation of transmitter release. J. Physiol. 509, 2.
116. 2+ stores in neurons: Molecular, structural and functional properties. Prog. Neurobiol. 65(3), 309-338.
117. Middleton, F. A., Mirnics, K., Pierri, J. N., Lewis, D. A., and Levitt, P. (2002). Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22, 2718-2729.
118. Miller, R. J. (1998). Mitochondria: The kraken wakes. TINS 21, 95-97.
119. Mizino, Y., Suzuki, K., and Ohta, S. (1990). Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J. Neurol. Sci. 96, 49-57.
120. Mori, H., and Mishina, M. (1995). Structure and function of the NMDA receptor channel. Neuropharmacology 34, 1219-1237.
121. Mulcrone, J., Whatley, S. A., Ferrier, I. N., and Marchbanks, R. M. (1995). A study of altered gene expression in frontal cortex from schizophrenic patients using differential screening. Schizobhr. Res. 14, 203-213.
122. Nicholls, D. G., and Budd, S. L. (2000). Mitochondria and neuronal survival. Physiol. Rev. 80, 316-344.
123. Nunes, M. C., Roy, N. S., Keyong, H. M., Goodman, R. R., McKhann, G., Jiang, L., Kang, J., Nedergaard, M., and Goldman, S. A. (2003). Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nature Med. 9(4), 439-447.
124. Ohnuma, T., Kato, H., Arai, H., Faull, R. L., McKenna, P. J., and Emson, P. C. (2000). Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11, 3133-3137.
125. Pall, H. S., Williams, A. C., Blake, D. R., and Lunec, J. (1987). Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2, 596-599.
126. Parish, C. L., Stanic, D., Drago, J., Borrelli, E., Finkelstein, D. I., and Horne, M. K. (2002). Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur. J. Neurosci. 16, 787-794.
127. Perrone-Bizzozero, N. I., Sower, A. C., Bird, E. D., Benowitz, L. I., Ivins, K. J., and Neve, R. L. (1996). Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. USA 93, 14182-14187.
128. Potkin, S. G., Alva, G., Fleming, K., Anand, R., Keator, D., Carreon, D., Doo, M., Jin, Y., Wu, J. C., and Fallon, J. H. (2002). A PET study of the pathophysiology of negative symptoms in schizophrenia: Positron emission tomography. Am. J. Psychiat. 159, 227-237.
129. Prince, J. A., Blennow, K., Gottfries, C. G., Karlsson, I., and Oreland, L. (1997a). Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 21, 372-379.
130. Prince, J. A., Harro, J., Blennow, K., Gottfries, C. G., Karlsson, I., and Oreland, L. (2000). Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology 22, 284-292.
131. Prince, J. A., Yassin, M., and Oreland, L. (1998). A histochemical demonstration of altered cytochrome c oxidase activity in the rat brain by neuroleptics. Eur. Neuropsychopharmacol. 8, 1-6.
132. Prince, J. A., Yassin, M. S., and Oreland, L. (1997b). Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther. 280, 261-267.
133. Przedborski, S., Jackson-Lewis, V., Muthane, U., Jiang, H., Ferreria, M., Naini, A. B., and Fahn, S. (1993). Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34, 715-723.
134. 2+ pools in neuronal signaling. Curr. Opin. Neurobiol. 11, 306-311.
135. Seeman, P. (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133-152.
136. Selemon, L. D., Rajkowska, G., and Goldman-Rakic, P. S. (1998). Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 392, 402-412.
137. Shenton, M. E., Dickey, C. C., Frumin, M., and McCarley, R. W. (2001). A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52.
138. Sherman, S. M., and Spear, P. D. (1982). Organization of visual pathways in normal and visually deprived cats. Physiol. Rev. 62, 738-755.
139. Shifman, S., Bronstein, M., Sternfeld, M., Pisante-Shalom, A., Lev-Lehman, E., Weizman, A., Reznik, I., Spivak, B., Grisaru, N., Karp, L., Schiffer, R., Kotler, M., Strous, R. D., Swartz-Vanetik, M., Knobler, H. Y., Shinar, E., Beckmann, J. S., Yakir, B., Risch, N., Zak, N. B., and Darvasi, A. (2002). A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71, 1296-1302.
140. Smythies, J. (1997). The biochemical basis of synaptic plasticity and neurocomputation: A new theory. Proc. R. Soc. Lond. B 264, 575-579.
141. Srivastava, N., Barthwal, M. K., Dalal, P. K., Agarwal, A. K., Nag, D., Srimal, R. C., Seth, P. K., and Dikshit, M. (2001). Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 158, 140-145.
142. Tamminga, C. A., Thaker, G. K., Buchanan, R., Kirkpatrick, B., Alphs, L. D., Chase, T. N., and Carpenter, W. T. (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiat. 49, 522-530.
143. Tsai, G., Goff, D. C., Chang, R. W., Flood, J., Baer, L., and Coyle, J. T. (1998). Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiat. 155, 1207-1213.
144. Tsai, G., Passani, L. A., Slusher, B. S., Carter, R., Baer, L., Kleinman, J. E., and Coyle, J. T. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiat. 52, 829-836.
145. Turpaev, K. T. (2002). Reactive oxygen species and regulation of gene expression. Biochemistry 67, 281-292.
146. Uranova, N., Orlovskaya, D., Vikhreva, O., Zimina, I., Kolomeets, N., Vostrikov, V., and Rachmanova, V. (2001). Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 55, 597-610.
147. Uranova, N., Orlovskaya, D., Vikhreva, O., Zimina, I., Kolomeets, N., Vostrikov, V., Uranova, N. A., Casanova, M. F., DeVaughn, N. M., Orlovskaya, D. D., and Denisov, D. V. (1996). Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr. Res. 22, 81-83.
148. Uranova, N. A., and Aganova, E. A. (1998). Ultrastructure of synapses of the anterior limbic cortex in schizophrenia. Zhurnal Neuropatologii I Psikhiatrii Imeni S-S-Korsakova 89, 56-59.
149. Volz, H. R., Riehemann, S., Maurer, I., Smesny, S., Sommer, M., Rzanny, R., Holstein, W., Czekalla, J., and Sauer, H. (2000). Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: A 31 Pchemical shift spectroscopic-imaging study. Biol. Psychiat. 47, 954-961.
150. Weeber, E. J., Levy, M., Sampson, M. J., Anflous, K., Armstrong, D. L., Brown, S. E., Sweatt, J. D., and Craigen, W. J. (2002). The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J. Biol. Chem. 277, 18891-18897.
151. Weinberger, D. R. (1996). On the plausibility of the neurodevelopmental hypothesis in schizophrenia. Neuropsychopharmacology 14, 1S-11S.
152. Weinberger, D. R. (1999). Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiat. 45, 395-402.
153. Weinberger, D. R., Berman, K. F., and Zec, R. F. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiat. 43, 114-124.
154. Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., and Goldberg, T. E. (2001). Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiat. 50, 825-844.
155. Whatley, S. A., Curi, D., and Das Gupta, F. (1998). Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Mol. Psychiat. 3, 227-237.
156. Whatley, S. A., Curi, D., and Marchbanks, R. M. (1996). Mitochondrial involvement in schizophrenia and other functional psychoses. Neuroch. Res. 21, 995-1004.
157. Wieraszko, A. (1996). Extracellular ATP as a neurotransmitter: Its role in synaptic plasticity in the hippocampus. Acta Neurobiol. Exp. 56, 637-648.
158. Williams, J. M., Thompson, V. L., Mason-Parker, S. E., Abraham, W. C., and Tate, W. P. (1998). Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Brain Res. Mol. Brain Res. 60, 50-56.
159. Willner, P. (1997). The dopamine hypothesis of schizophrenia: Current status, future prospects. Int. Clin. Psychopharmacol. 12, 297-308.
160. Wong-Riley, M. (1989). Cytochrome c oxidase: An endogenous metabolic marker for neuronal activity. TINS 12, 94-101.
161. Yang, C., Silver, B., Ellis, S. R., and Mower, G. D. (2001). Bidirectional regulation of mitochondrial gene expression during developmental neuroplasticity of visual cortex. Biochem. Biophys. Res. Commun. 287, 1070-1074.
162. Yanik, M., Vural, H., Kocyigit, A., Tutkun, H., Zoroglu, S. S., Herken, H., Savas, H. A., Koylu, A., and Akyol, O. (2003). Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology 47, 61-65.
163. Zoroglu, S. S., Herken, H., Yurekli, M., Uz, E., Tutkun, H., Savas, H. A., Bagci, C., Ozen, M. E., Cengiz, B., Cakmak, E. A., Dogru, M. I., and Akyol, O. (2002). The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J. Psychiat. Res. 36, 309-315.
164. Zucker, R. S. (1999). Calcium- and activity-dependent synaptic plasticity. Curr. Opin. Neurobiol. 9, 305-313.